--- title: "首次公開募股動態：Seaport Therapeutics 增加了 IPO 的規模，並將其定價為 18 美元——處於定價區間的高端" type: "News" locale: "zh-HK" url: "https://longbridge.com/zh-HK/news/284896142.md" description: "Seaport Therapeutics（SPTX），一家位於波士頓的生物科技公司，已將其首次公開募股（IPO）規模增加至 1416 萬股，定價為 18.00 美元，籌集資金為 2.5488 億美元。該股票將於 2026 年 5 月 1 日在納斯達克交易。公司計劃將籌集的資金用於其治療重度抑鬱症藥物的第二階段臨牀試驗。按此定價，Seaport Therapeutics 的市值為 9.545 億美元。高盛等公司是此次 IPO 的聯合主承銷商" datetime: "2026-05-01T12:00:58.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/284896142.md) - [en](https://longbridge.com/en/news/284896142.md) - [zh-HK](https://longbridge.com/zh-HK/news/284896142.md) --- # 首次公開募股動態：Seaport Therapeutics 增加了 IPO 的規模，並將其定價為 18 美元——處於定價區間的高端 **Seaport Therapeutics (SPTX), a Boston-based biotech developing drugs to treat major depression, increased its IPO’s size at pricing – to 14.16 million shares – up from 11.8 million in the prospectus – and priced its IPO at $18.00 – the top of its range – to raise $254.88 million on Thursday night, April 30, 2026.** **Shares of Seaport Therapeutics are set to start trading today – Friday, May 1, 2026 – on the NASDAQ.** **Goldman Sachs, J.P. Morgan, Leerink Partners, Citigroup and Stifel are the joint book-runners.** **At pricing, Seaport Therapeutics had a market cap of $954.5 million.** **Seaport Therapeutics (SPTX) intends to use the IPO’s proceeds to help fund the Phase 2 clinical trials of its leading drug candidates, GlyphAllo (SPT-300) and GlyphAgo (SPT-320), to treat major depression, including postpartum depression.** **The company is not profitable.** **(For more information about this company, please check the IPO Calendar and the individual IPO Profile found on the IPOScoop.com website.)** **Note: Never trade on proposed symbols. They have been known to change and you might buy something on the OTC Bulletin Board.** **To see what time the NASDAQ IPOs are expected to trade, please log in to: NASDAQTrader.com then scroll down to IPO Message.** **Disclosure: Nobody on the IPOScoop.com staff has a position in any stocks mentioned above, nor do they trade or invest in IPOs. The IPOScoop.com staff does not issue advice, recommendations or opinions.** ### 相關股票 - [SEELQ.US](https://longbridge.com/zh-HK/quote/SEELQ.US.md) - [SEEL.US](https://longbridge.com/zh-HK/quote/SEEL.US.md) - [BBH.US](https://longbridge.com/zh-HK/quote/BBH.US.md) - [IBB.US](https://longbridge.com/zh-HK/quote/IBB.US.md) - [FBT.US](https://longbridge.com/zh-HK/quote/FBT.US.md) - [IBBQ.US](https://longbridge.com/zh-HK/quote/IBBQ.US.md) - [SBIO.US](https://longbridge.com/zh-HK/quote/SBIO.US.md) - [BIB.US](https://longbridge.com/zh-HK/quote/BIB.US.md) - [PBE.US](https://longbridge.com/zh-HK/quote/PBE.US.md) - [ARKG.US](https://longbridge.com/zh-HK/quote/ARKG.US.md) - [LABU.US](https://longbridge.com/zh-HK/quote/LABU.US.md) - [XBI.US](https://longbridge.com/zh-HK/quote/XBI.US.md) - [GS.US](https://longbridge.com/zh-HK/quote/GS.US.md) - [JPM.US](https://longbridge.com/zh-HK/quote/JPM.US.md) - [C.US](https://longbridge.com/zh-HK/quote/C.US.md) - [SF.US](https://longbridge.com/zh-HK/quote/SF.US.md) - [NDAQ.US](https://longbridge.com/zh-HK/quote/NDAQ.US.md) - [W4VR.SG](https://longbridge.com/zh-HK/quote/W4VR.SG.md) - [JPM-M.US](https://longbridge.com/zh-HK/quote/JPM-M.US.md) - [JPM-C.US](https://longbridge.com/zh-HK/quote/JPM-C.US.md) - [JPM-D.US](https://longbridge.com/zh-HK/quote/JPM-D.US.md) - [JPM-L.US](https://longbridge.com/zh-HK/quote/JPM-L.US.md) - [8634.JP](https://longbridge.com/zh-HK/quote/8634.JP.md) - [JPM-K.US](https://longbridge.com/zh-HK/quote/JPM-K.US.md) - [JPM-J.US](https://longbridge.com/zh-HK/quote/JPM-J.US.md) - [C-R.US](https://longbridge.com/zh-HK/quote/C-R.US.md) - [SF-C.US](https://longbridge.com/zh-HK/quote/SF-C.US.md) - [SFB.US](https://longbridge.com/zh-HK/quote/SFB.US.md) - [SF-B.US](https://longbridge.com/zh-HK/quote/SF-B.US.md) - [SF-D.US](https://longbridge.com/zh-HK/quote/SF-D.US.md) ## 相關資訊與研究 - [巨生醫獲 SelectUSA 醫療科技組金牌 啟動美國 A 輪募資目標 1000 萬美元](https://longbridge.com/zh-HK/news/286905054.md) - [鉅亨速報 - Factset 最新調查：Roivant Sciences LtdROIV-US 的目標價調升至 38 元，幅度約 8.57%](https://longbridge.com/zh-HK/news/287126179.md) - [儲局會議記錄顯示 大多數官員警告通脹率若持續高於 2% 需考慮加息](https://longbridge.com/zh-HK/news/287171073.md) - [健康綜述：廣泛使用的哮喘藥物或可提升癌症免疫療法療效](https://longbridge.com/zh-HK/news/286957357.md) - [花旗看好催化劑與增長前景，覆蓋 Ionis、Alnylam、BioMarin 並給予買入評級](https://longbridge.com/zh-HK/news/286956616.md)